Amyloid’s false promise—no cognitive improvement and 40% brain swelling risk—can’t compete with Xanamem’s cortisol-driven approach, which showed measurable improvements in attention and working memory in older adults, with no brain swelling and a clean safety profile. BVF’s exit likely reflects fund rotation, not Xanamem’s potential. With the 100-patient milestone announcement expected soon and interim Phase 2b data on the horizon, ACW’s real value will shine once short-term trading noise fades.
Amyloid’s false promise—no cognitive improvement and 40% brain...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $63.54M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.1¢ | 1.9¢ | $128.6K | 6.390M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 3337643 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 1075545 | 5 |
View Market Depth
| Last trade - 15.57pm 13/06/2025 (20 minute delay) ? |
| ACW (ASX) Chart |